$4.98
0.10% yesterday
Nasdaq, May 20, 09:46 pm CET
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

bluebird bio, Inc. Stock price

$4.98
+1.08 27.69% 1M
-1.08 17.82% 6M
-3.36 40.29% YTD
-15.62 75.83% 1Y
-60.42 92.39% 3Y
-838.77 99.41% 5Y
-2,140.46 99.77% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.00 0.00%
ISIN
US09609G1004
Symbol
BLUE
Sector
Industry

Key metrics

Market capitalization $48.77m
Enterprise Value $157.92m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.52
P/S ratio (TTM) P/S ratio 0.47
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 127.51%
Revenue (TTM) Revenue $103.95m
EBIT (operating result TTM) EBIT $-210.51m
Free Cash Flow (TTM) Free Cash Flow $-230.47m
Cash position $78.78m
EPS (TTM) EPS $-20.61
P/E forward negative
P/S forward 0.20
EV/Sales forward 0.63
Short interest 4.39%
Show more

Is bluebird bio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

bluebird bio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a bluebird bio, Inc. forecast:

1x Buy
33%
2x Hold
67%

Analyst Opinions

3 Analysts have issued a bluebird bio, Inc. forecast:

Buy
33%
Hold
67%

Financial data from bluebird bio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
104 104
128% 128%
100%
- Direct Costs 91 91
56% 56%
88%
13 13
199% 199%
12%
- Selling and Administrative Expenses 75 75
49% 49%
72%
- Research and Development Expense 87 87
42% 42%
84%
-149 -149
52% 52%
-144%
- Depreciation and Amortization 61 61
132% 132%
59%
EBIT (Operating Income) EBIT -211 -211
37% 37%
-203%
Net Profit -200 -200
32% 32%
-192%

In millions USD.

Don't miss a Thing! We will send you all news about bluebird bio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

bluebird bio, Inc. Stock News

Neutral
Business Wire
4 days ago
SOMERVILLE, Mass.--(BUSINESS WIRE)--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), have amended their definitive agreement pursuant to which Carlyle and SK Capital will purchase all of the outstanding shares of bluebird. The parties have issued the following updated instruction...
Positive
Proactive Investors
6 days ago
Shares of bluebird bio Inc (NASDAQ:BLUE) surged 50% on Wednesday after the gene therapy developer announced an amended acquisition agreement with private equity firms Carlyle and SK Capital, offering shareholders a higher upfront cash payout. The revised deal includes a $5 per share cash offer, replacing a previous bid that had offered $3 per share upfront and a contingent value right (CVR) of ...
Positive
Reuters
7 days ago
Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker.
More bluebird bio, Inc. News

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.

Head office United States
CEO Andrew Obenshain
Employees 248
Founded 1992
Website www.bluebirdbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today